United States· US:52856-601_9a102e64-6ff8-41bd-8195-932aaf85b31c
KEBILIDI
A eladocagene exuparvovec product containing eladocagene exuparvovec, registered in United States by PTC Therapeutics, Inc.. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Eladocagene exuparvovec is registered in 10 of 19 countries.
Countries holding a registration under ATC A16AB26 (eladocagene exuparvovec), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Eladocagene exuparvovec · ATC A16AB26
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ELADOCAGENE EXUPARVOVEC
- Manufacturer
- PTC Therapeutics, Inc.
- Country
- United States (US)
- ATC code
- A16AB26
- ATC class
- Eladocagene exuparvovec
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1152856-601-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eladocagene exuparvovec in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUpstaza 2.8 10*11 vg/0.5 mlPTC Therapeutics International
- CzechiaUPSTAZAPTC Therapeutics International Limited, Dublin 2
- SpainUPSTAZA 2,8 × 10E11 GENOMAS VECTORIALES (VG)/0,5 ML PARA SOLUCION PARA PERFUSIONPtc Therapeutics International Limited
- FinlandUpstazaPTC Therapeutics International limited
- FranceUPSTAZA 2,8 x 100 000 000 000 génomes de vecteur (vg)/0,5 mL, solution pour perfusionPTC THERAPEUTICS INTERNATIONAL (IRLANDE)
- United KingdomUpstaza 280 giga vector genomes/0.5ml solution for infusion vialsPTC Therapeutics Ltd
- IrelandUpstaza 2.8 × 10^11 vector genomes/0.5 mL solution for infusionPTC Therapeutics International Limited
- IcelandUpstazaPTC Therapeutics International Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Upstaza
- Liechtenstein · Upstaza
- Norway · Upstaza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1a263b1-f170-4828-be4d-a2dbdaa726d5 GET /v1/drugs/f1a263b1-f170-4828-be4d-a2dbdaa726d5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRACEREBRAL",
"source": "ndc",
"strength": "560000000000",
"substance": "ELADOCAGENE EXUPARVOVEC",
"productndc": "52856-601",
"dosage_form": "SUSPENSION",
"dea_schedule": null,
"strength_unit": "{GC}/mL",
"application_number": "BLA125722",
"marketing_category": "BLA"
}See everything about eladocagene exuparvovec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.